{
  "name": "Neuro On-Call Quick References",
  "slug": "neuro-on-call",
  "icon": "ğŸš¨",
  "color": "bg-rose-100 text-rose-800 border-rose-200",
  "toc": [
    {
      "level": 2,
      "text": "Seizure & Status Epilepticus",
      "id": "status-epilepticus"
    },
    {
      "level": 2,
      "text": "Seizure Medications & Dosing",
      "id": "seizure-medications"
    },
    {
      "level": 2,
      "text": "Stroke",
      "id": "stroke"
    },
    {
      "level": 2,
      "text": "Pediatric LVO Escalation Pathway",
      "id": "lvo-escalation"
    },
    {
      "level": 2,
      "text": "Migraine Pathway â€” Quick Reference",
      "id": "migraine-pathway-quick-reference"
    },
    {
      "level": 2,
      "text": "Clinical Reference Images",
      "id": "clinical-reference-images"
    }
  ],
  "html": "<section aria-label=\"Seizure &amp; Status Epilepticus\">\n<div style=\"display:flex;align-items:flex-start;gap:0.875rem;background:#fef2f2;border-left:4px solid #dc2626;border-radius:0 10px 10px 0;padding:1rem 1.25rem 1rem 1.25rem;margin:2.5rem 0 1.25rem;\">\n  <span style=\"font-size:1.75rem;line-height:1;flex-shrink:0;margin-top:0.1rem;\" aria-hidden=\"true\">âš¡</span>\n  <div style=\"flex:1;min-width:0;\">\n    <h2 id=\"status-epilepticus\" style=\"margin:0 0 0.25rem;padding:0;font-size:1.1rem;font-weight:700;color:#dc2626;border:none;background:none;\">Seizure &amp; Status Epilepticus</h2>\n    <p style=\"margin:0;font-size:0.75rem;color:#dc2626;opacity:0.85;\">Acute management pathways, visual protocols, and pocket reference cards</p>\n  </div>\n</div><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/status-pathway.jpeg\" alt=\"Status Epilepticus Pathway\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  <figcaption style=\"text-align:center;font-size:0.75rem;color:#64748b;margin-top:0.5rem;font-style:italic;\">Status Epilepticus Pathway</figcaption>\n</figure><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/neonatal-seizures.png\" alt=\"Neonatal Seizures Reference\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  <figcaption style=\"text-align:center;font-size:0.75rem;color:#64748b;margin-top:0.5rem;font-style:italic;\">Neonatal Seizures Reference</figcaption>\n</figure><div style=\"margin:1.25rem 0;border-radius:10px;overflow:hidden;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);\">\n  <div style=\"padding:0.6rem 0.875rem;background:#f8fafc;border-bottom:1px solid #e2e8f0;display:flex;align-items:center;justify-content:space-between;gap:0.5rem;flex-wrap:wrap;\">\n    <span style=\"font-size:0.8rem;font-weight:600;color:#1e293b;\">ğŸ“„ YES Epilepsy Pocket Card</span>\n    <a href=\"/pdfs/neuro-on-call/yes-pocketcard-epi-med-v3.pdf\" target=\"_blank\" rel=\"noopener\" style=\"font-size:0.75rem;color:#2563eb;white-space:nowrap;text-decoration:none;background:#eff6ff;border:1px solid #bfdbfe;border-radius:6px;padding:0.25rem 0.6rem;\">Open / Download â†—</a>\n  </div>\n  <object data=\"/pdfs/neuro-on-call/yes-pocketcard-epi-med-v3.pdf\" type=\"application/pdf\" width=\"100%\" style=\"display:block;background:#fafafa;\" class=\"pdf-embed\">\n    <div style=\"padding:2rem;text-align:center;\">\n      <p style=\"margin:0 0 0.75rem;color:#64748b;font-size:0.875rem;\">PDF preview not available.</p>\n      <a href=\"/pdfs/neuro-on-call/yes-pocketcard-epi-med-v3.pdf\" target=\"_blank\" rel=\"noopener\" style=\"color:#2563eb;font-size:0.875rem;\">ğŸ“„ Open PDF</a>\n    </div>\n  </object>\n</div><div style=\"margin:1.25rem 0;border-radius:10px;overflow:hidden;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);\">\n  <div style=\"padding:0.6rem 0.875rem;background:#f8fafc;border-bottom:1px solid #e2e8f0;display:flex;align-items:center;justify-content:space-between;gap:0.5rem;flex-wrap:wrap;\">\n    <span style=\"font-size:0.8rem;font-weight:600;color:#1e293b;\">ğŸ“„ Seizure Protocol Reference</span>\n    <a href=\"/pdfs/neuro-on-call/913888-1.pdf\" target=\"_blank\" rel=\"noopener\" style=\"font-size:0.75rem;color:#2563eb;white-space:nowrap;text-decoration:none;background:#eff6ff;border:1px solid #bfdbfe;border-radius:6px;padding:0.25rem 0.6rem;\">Open / Download â†—</a>\n  </div>\n  <object data=\"/pdfs/neuro-on-call/913888-1.pdf\" type=\"application/pdf\" width=\"100%\" style=\"display:block;background:#fafafa;\" class=\"pdf-embed\">\n    <div style=\"padding:2rem;text-align:center;\">\n      <p style=\"margin:0 0 0.75rem;color:#64748b;font-size:0.875rem;\">PDF preview not available.</p>\n      <a href=\"/pdfs/neuro-on-call/913888-1.pdf\" target=\"_blank\" rel=\"noopener\" style=\"color:#2563eb;font-size:0.875rem;\">ğŸ“„ Open PDF</a>\n    </div>\n  </object>\n</div>\n</section>\n<section aria-label=\"Seizure Medications &amp; Dosing\">\n<div style=\"display:flex;align-items:flex-start;gap:0.875rem;background:#f5f3ff;border-left:4px solid #7c3aed;border-radius:0 10px 10px 0;padding:1rem 1.25rem 1rem 1.25rem;margin:2.5rem 0 1.25rem;\">\n  <span style=\"font-size:1.75rem;line-height:1;flex-shrink:0;margin-top:0.1rem;\" aria-hidden=\"true\">ğŸ’Š</span>\n  <div style=\"flex:1;min-width:0;\">\n    <h2 id=\"seizure-medications\" style=\"margin:0 0 0.25rem;padding:0;font-size:1.1rem;font-weight:700;color:#7c3aed;border:none;background:none;\">Seizure Medications &amp; Dosing</h2>\n    <p style=\"margin:0;font-size:0.75rem;color:#7c3aed;opacity:0.85;\">Anti-seizure medication reference table, benzodiazepine dosing, and weight-based guides</p>\n  </div>\n</div><div class=\"doc-content\" style=\"margin-top:1rem;\"><h3><strong>Diastat/Diazepam Dosing (Weight Based)</strong></h3></div><div class=\"table-wrap\">\n<table>\n<tbody>\n<tr><th>Generic&nbsp;[Trade]</th><th>Abbrev&nbsp;(Yr)</th><th>FDAâ€‘Labeledâ€¯Indication</th><th>Formulation&nbsp;(Â§â€¯=â€¯generic)</th><th>Costâ€ </th><th>Mechanism of&nbsp;Action</th><th>Adult Dose&nbsp;(mg/day) initial&nbsp;â†’&nbsp;max</th><th>Child Dose initialâ€¯;&nbsp;maint&nbsp;mg/kg/day</th><th>Typical Dose increases </th><th>Time âœ&nbsp;Steadyâ€‘State&nbsp;/&nbsp;PKTÂ½&nbsp;(h),&nbsp;%&nbsp;bound&nbsp;[ther.&nbsp;levelâ€¯Î¼g/mL]</th><th>Key Drug&nbsp;Interactions</th><th>Common / Serious&nbsp;Adverseâ€¯Effects</th><th>Notes&nbsp;&amp;&nbsp;Pearls</th><th>Monitoring / â€œTo&nbsp;Doâ€</th></tr>\n<tr><td>Acetazolamide&nbsp;[Diamox]</td><td>AZM&nbsp;(1952)</td><td>Adjunct for various seizure types (off-label)</td><td>Tab, IV</td><td>$</td><td>Carbonic anhydrase inhibitor</td><td>250â€¯â†’â€¯1000 (BID-TID)</td><td>5â€¯;â€¯10â€“15</td><td>â†‘ 250 mg q1â€“2wk (ad); â†‘ 5 mg/kg/d q1â€“2wk (p)</td><td>2â€“3â€¯d;&nbsp;TÂ½&nbsp;6â€“9â€¯h, 90â€¯%</td><td>May alter excretion of other drugs (e.g., lithium)</td><td>Paresthesia, fatigue / metabolic acidosis, nephrolithiasis</td><td>Tolerance may develop; not first-line; catamenial epilepsy</td><td>Electrolytes/renal funtion, CBC</td></tr>\n<tr><td>Brivaracetamâ€¯[Briviact]</td><td>BRV&nbsp;(2016)</td><td>Adj. focal</td><td>Tabs, soln, IV</td><td>$$</td><td>Highâ€‘affinity&nbsp;SV2A</td><td>50â€¯â†’â€¯200</td><td>1â€¯;â€¯2â€“5&nbsp;(BID)</td><td>â†‘ 25â€“50 mg q1â€“2wk (ad); â†‘ 1 mg/kg/d q1â€“2wk (p)</td><td>2â€¯d;&nbsp;TÂ½â€¯9â€¯h, 20â€¯%</td><td>Minor CYP2C19</td><td>Somnolence, dizziness</td><td>Faster IV push vs&nbsp;LEV</td><td>LFT in hepatic&nbsp;dz</td></tr>\n<tr><td>Cannabidiolâ€¯[Epidiolex]</td><td>CBD&nbsp;(2018)</td><td>Dravet,&nbsp;LGS,&nbsp;TSC</td><td>Oral solnâ€¯100â€¯mg/mL</td><td>$$$</td><td>ECS /&nbsp;TRPV1 modulator</td><td>100â€¯â†’â€¯700â€¯mg (wtâ€‘based)</td><td>5â€¯;â€¯10â€“20&nbsp;(maxâ€¯25)&nbsp;BID</td><td>â†‘ 2.5â€“5 mg/kg/d q1â€“2wk</td><td>2â€“4â€¯wk;&nbsp;TÂ½â€¯56â€“61&nbsp;h, 94â€¯%&nbsp;[â€”]</td><td>â†‘&nbsp;CLB, â†‘&nbsp;everolimus (CYP2C19/3A)</td><td>Diarrhea, â†“&nbsp;appetite / â†‘LFT</td><td>Weightâ€‘based; hold â‰¥â€¯3Ã—â€¯ULN&nbsp;ALT</td><td>LFT qâ€¯month Ã—â€¯3, then qâ€¯3â€“6â€¯m</td></tr>\n<tr><td>Carbamazepineâ€¯[Tegretol]</td><td>CBZ&nbsp;(1968)</td><td>Focal, trigeminal&nbsp;neuralgia</td><td>Tabs, suspÂ§</td><td>$</td><td>Naâº block</td><td>200â€¯â†’â€¯1600</td><td>5â€¯;â€¯10â€“30&nbsp;(BID)</td><td>â†‘ 200 mg/d qwk (ad); â†‘ 2â€“5 mg/kg/d qwk (p)</td><td>Autoâ€‘induction&nbsp;3â€¯wk;&nbsp;TÂ½â€¯12â€“17â€¯h, 80â€¯%&nbsp;[4â€“12]</td><td>Strong inducer; â†“â€¯OCP, CLZ</td><td>Diplopia, rash /&nbsp;aplastic&nbsp;anemia,&nbsp;SJS/TEN</td><td>HLAâ€‘B*15:02 in Asians</td><td>CBC, Na, LFT qâ€¯6â€¯m</td></tr>\n<tr><td>Cenobamateâ€¯[Xcopri]</td><td>CNB&nbsp;(2019)</td><td>Focalâ€¯(adult)</td><td>Tabs</td><td>$$</td><td>Naâº lateâ€‘block, GABA-A modulator</td><td>50â€¯â†’â€¯400</td><td>â€” (not FDAâ€¯peds)</td><td>â†‘ 50 mg q2wk (ad; not FDA peds)</td><td>4â€¯wk;â€¯TÂ½â€¯50â€“60â€¯h, 60â€¯%</td><td>&nbsp;Induce CYP3A</td><td>Somnolence, DRESS</td><td>Offâ€‘label trials â‰¥12â€¯y</td><td>Titrate slowly; rash watch</td></tr>\n<tr><td>Clobazam (Onfi)</td><td>CLB (2011)</td><td>LGS (â‰¥2â€¯y)</td><td>Tabs, susp 2.5 mg/1mL</td><td>$$</td><td>GABA-A modulator</td><td>10 â†’ 40</td><td>0.25; 0.5-1.0 (divided BID)</td><td>â†‘ 5â€“10 mg/d qwk (ad); â†‘ 0.1â€“0.2 mg/kg/d qwk (p)</td><td>SS 5â€“9â€¯d; TÂ½ 36â€“42â€¯h; ~85% [0.1â€“0.4]</td><td>CYP3A4/2C19 sub; â†‘ by CBD/flucon.; â†“ by CBZ/PHT/PB</td><td>Somn., drooling, behav. change / resp. dep., SJS, WD sz</td><td>Sch.&nbsp;IV; toleranceâ€”consider drug holidays; taper slow; offâ€‘label: focal</td><td>Sedation/behavior; LFT if hepatic dz; caution w/ opioids</td></tr>\n<tr><td>Clonazepam&nbsp;[Klonopin]</td><td>CLZ&nbsp;(1975)</td><td>Lennox-Gastaut, absence, myoclonic</td><td>Tab, ODT</td><td>$</td><td>GABA-A modulator</td><td>0.5â€¯â†’â€¯20 (div BID-TID)</td><td>0.01â€¯;â€¯0.05â€“0.1 (div BID-TID)</td><td>â†‘ 0.25â€“0.5 mg q3d (ad); â†‘ 0.01â€“0.03 mg/kg/d q3d (p)</td><td>3â€“5â€¯d;&nbsp;TÂ½&nbsp;30â€“40â€¯h, 85â€¯%</td><td>Additive CNS depression with other ASMs</td><td>Sedation, ataxia / dependence, respiratory depression</td><td>Taper slowly to avoid withdrawal seizures</td><td>Monitor sedation, respiratory status in polytherapy</td></tr>\n<tr><td>Eslicarbazepine&nbsp;[Aptiom]</td><td>ESL&nbsp;(2013)</td><td>Focal epilepsy (adjunct/monotherapy)</td><td>Tab</td><td>$$</td><td>Prolongs Naâº inactivation</td><td>400â€¯â†’â€¯1200&nbsp;QD</td><td>10â€¯;â€¯20â€“30 (div QD)</td><td>â†‘ 400â€“600 mg qwk (ad); â†‘ 5â€“10 mg/kg/d qwk (p)</td><td>4â€“5â€¯d;&nbsp;TÂ½&nbsp;20â€“24â€¯h, 40â€¯%</td><td>â†“ by strong enzyme inducers</td><td>Dizziness, hyponatremia / rash, DRESS</td><td>Once-daily dosing; monitor Naâº</td><td>BMP baseline &amp; periodic (Naâº)</td></tr>\n<tr><td>Ethosuximideâ€¯[Zarontin]</td><td>ETX&nbsp;(1958)</td><td>CAE</td><td>Caps, suspÂ§</td><td>$</td><td>Tâ€‘CaÂ²âº block</td><td>500â€¯â†’â€¯1500</td><td>10â€¯;â€¯20â€“40&nbsp;(BID)</td><td>â†‘ 250 mg q4â€“7d (ad); â†‘ 5 mg/kg/d q4â€“7d (p)</td><td>1â€¯wk;&nbsp;TÂ½â€¯30â€“60â€¯h, &lt;10â€¯%&nbsp;[40â€“100]</td><td>â†“â€¯by&nbsp;EIAEDs</td><td>GI upset, hiccups /&nbsp;SJS</td><td>Take&nbsp;with food/full Hâ‚‚O</td><td>CBC, LFT qâ€¯6â€¯m</td></tr>\n<tr><td>Felbamateâ€¯[Felbatol]</td><td>FBM&nbsp;(1993)</td><td>LGS, refractory focal</td><td>Tabs, susp</td><td>$$</td><td>NMDA antag, GABAâ†‘</td><td>1200â€¯â†’â€¯3600</td><td>15â€¯;â€¯30â€“60 (TID)</td><td>â†‘ 600 mg q1â€“2wk (ad); â†‘ 15 mg/kg/d q1â€“2wk (p)</td><td>1â€“2â€¯wk;&nbsp;TÂ½â€¯20â€¯h, 25â€¯%</td><td>Strong inducer &amp;&nbsp;inhib</td><td>Insomnia /&nbsp;aplastic anemia,&nbsp;hepatic&nbsp;fail</td><td>Signed consent required</td><td>CBC, LFT monthly</td></tr>\n<tr><td>Fenfluramineâ€¯[Fintepla]</td><td>FFA&nbsp;(2020)</td><td>Dravet,&nbsp;LGS</td><td>Oral soln&nbsp;2.2â€¯mg/mL</td><td>$$$</td><td>5â€‘HT2B/2C agonist</td><td>2â€¯â†’â€¯26â€¯mg</td><td>0.2â€¯;â€¯0.35â€“0.7</td><td>Varies â€“ see full dosing guidelines</td><td>1â€“2â€¯wk;&nbsp;TÂ½â€¯20â€“30â€¯h, 50â€¯%&nbsp;[â€”]</td><td>SSRIs/SNRIs â‡’ 5â€‘HT&nbsp;syndrome</td><td>â†“Appetite, somnolence /&nbsp;valvulopathy,&nbsp;QT</td><td>Dispense via REMS (echo,&nbsp;EKG)</td><td>Echo &amp;&nbsp;EKG baselineâ€¯+â€¯qâ€¯6â€¯m</td></tr>\n<tr><td>Gabapentinâ€¯[Neurontin]</td><td>GBP&nbsp;(1993)</td><td>Adj. focal, pain</td><td>Caps, solnÂ§</td><td>$</td><td>Î±2Î´â€‘CaÂ²âº mod</td><td>900â€¯â†’â€¯3600</td><td>10â€¯;â€¯30â€“60&nbsp;(TID)</td><td>â†‘ 300 mg q1â€“3d (ad); â†‘ 10 mg/kg/d q3d (p)</td><td>1â€¯d;&nbsp;TÂ½â€¯5â€“7â€¯h, 0â€¯%</td><td>â†“&nbsp;bioavail w/&nbsp;antacids</td><td>Sedation, wt gain</td><td>Nonâ€‘linear abs; taper off</td><td>Renal dose adjust</td></tr>\n<tr><td>Ganaxoloneâ€¯[Ztalmy]</td><td>GNX&nbsp;(2022)</td><td>CDKL5 deficiency</td><td>Oral&nbsp;susp&nbsp;50â€¯mg/mL</td><td>$$$</td><td>Neurosteroid GABAâ€‘A positive allosteric modulator</td><td>600â€¯â†’â€¯1800â€¯mg</td><td>7â€¯;â€¯21&nbsp;TID</td><td>Varies â€“ see full dosing guidelines</td><td>7â€¯d;&nbsp;TÂ½â€¯34â€¯h, 99â€¯%&nbsp;[â€”]</td><td>Substrate&nbsp;CYP3A4</td><td>Somnolence, fever /&nbsp;status&nbsp;sz</td><td>Administer&nbsp;with food</td><td>LFTs baseline &amp;â€¯periodic</td></tr>\n<tr><td>Lacosamideâ€¯[Vimpat]</td><td>LCM&nbsp;(2009)</td><td>Adj. focal</td><td>Tabs, soln, IV</td><td>$$</td><td>Slow Naâº inactivation</td><td>100â€¯â†’â€¯400</td><td>1â€¯;â€¯5â€“10&nbsp;(BID)</td><td>â†‘ 50 mg qwk (ad); â†‘ 1â€“2 mg/kg/d qwk (p)</td><td>3â€¯d;&nbsp;TÂ½â€¯13â€¯h,&nbsp;&lt;15â€¯%</td><td>Minimal</td><td>Dizziness, PRâ†‘ /&nbsp;AF&nbsp;rare</td><td>Screen ECG if cardiac&nbsp;hx</td><td>ECG if on PRâ€‘prolongers</td></tr>\n<tr><td>Lamotrigineâ€¯[Lamictal]</td><td>LTG&nbsp;(1994)</td><td>CAE, LGS, bipolar</td><td>Tabs, ODT,&nbsp;chewÂ§</td><td>$â€“$$</td><td>Naâº block, Tâ€‘CaÂ²âº</td><td>25â€¯â†’â€¯400</td><td>0.3â€¯;â€¯5â€“15 (slow titr)</td><td>â†‘ 25â€“50 mg q1â€“2wk (ad); â†‘ 0.2â€“0.6 mg/kg/d q1â€“2wk (p; slower w/ VPA)</td><td>4â€“8â€¯wk;&nbsp;TÂ½â€¯25â€¯h (â†‘&nbsp;VPA), 55â€¯%&nbsp;[â€”]</td><td>â†‘&nbsp;TÂ½&nbsp;w/&nbsp;VPA; â†“&nbsp;w/&nbsp;EIAEDs</td><td>Rash, insomnia /&nbsp;SJSâ€‘TEN</td><td>Split high daily dose to AM/PM</td><td>Educate rash signs</td></tr>\n<tr><td>Levetiracetamâ€¯[Keppra]</td><td>LEV&nbsp;(1999)</td><td>Broad incl.â€¯JME</td><td>Tabs, soln, IVÂ§</td><td>$$</td><td>SV2A binder</td><td>500â€¯â†’â€¯3000</td><td>10â€¯;â€¯20â€“60&nbsp;(BID)</td><td>â†‘ 500 mg q2wk (ad); â†‘ 10 mg/kg/d q2wk (p)</td><td>2â€¯d;&nbsp;TÂ½â€¯6â€“8â€¯h, &lt;10â€¯%&nbsp;[â€”]</td><td>Nil clinically</td><td>Irritability, somnolence</td><td>Pyridoxine may curb mood&nbsp;AE</td><td>Mood screen, behavior&nbsp;qâ€¯visit</td></tr>\n<tr><td>Methsuximide&nbsp;[Celontin]</td><td>MSX&nbsp;(1952)</td><td>Refractory absence seizures</td><td>Cap</td><td>$$</td><td>T-type CaÂ²âº channel blocker</td><td>300â€¯â†’â€¯1200 (div BID)</td><td>10â€¯;â€¯20â€“25</td><td>Varies â€“ see full dosing guidelines</td><td>3â€“7â€¯d;&nbsp;TÂ½&nbsp;60â€¯h, 0â€“50â€¯%</td><td>May â†‘ phenytoin; additive CNS effects</td><td>GI upset, drowsiness / blood dyscrasias, hepatotoxicity</td><td>Reserved for refractory cases</td><td>CBC, LFTs regularly</td></tr>\n<tr><td>Oxcarbazepineâ€¯[Trileptal]</td><td>OXC&nbsp;(2000)</td><td>Focal,&nbsp;2Â°&nbsp;GTC</td><td>Susp, tabsÂ§</td><td>$</td><td>Naâº block</td><td>300â€¯â†’â€¯2400</td><td>5â€¯;â€¯20â€“50&nbsp;(BID)</td><td>â†‘ 300 mg q3â€“7d (ad); â†‘ 5â€“10 mg/kg/d qwk (p)</td><td>3â€¯d;&nbsp;TÂ½&nbsp;MHD&nbsp;9â€¯h, &lt;40â€¯%</td><td>â†“&nbsp;OCP; crossâ€‘rxn&nbsp;CBZ</td><td>Hyponatremia, rash</td><td>Check Naâº espâ€¯elderly</td><td>Naâº&nbsp;qâ€¯6â€“12â€¯m</td></tr>\n<tr><td>Perampanelâ€¯[Fycompa]</td><td>PER&nbsp;(2012)</td><td>Focal, GTC</td><td>Tabs, susp</td><td>$$</td><td>Nonâ€‘comp AMPA antag</td><td>2â€¯â†’â€¯12&nbsp;mg QHS</td><td>(â‰¥4â€¯y) 2â€¯;â€¯4â€“8</td><td>â†‘ 2 mg q1â€“2wk (ad); â†‘ 0.04 mg/kg/d q1â€“2wk (p)</td><td>2â€“3â€¯wk;&nbsp;TÂ½â€¯105â€¯h, 95â€¯%</td><td>â†“&nbsp;by&nbsp;EIAEDs</td><td>Sedation, aggression /&nbsp;SUDEP signal</td><td>Blackâ€‘box:&nbsp;homicidal ideation</td><td>Psych screen qâ€¯visit</td></tr>\n<tr><td>Phenobarbital&nbsp;[Luminal]</td><td>PB&nbsp;(1912)</td><td>Neonatal,&nbsp;GTC</td><td>Elixir, tabsÂ§</td><td>$</td><td>GABAâ€‘A â†‘,&nbsp;Naâº block</td><td>60â€¯â†’â€¯300</td><td>3â€¯;â€¯5â€“10&nbsp;(QD)</td><td>â†‘ 30â€“60 mg qwk (ad); â†‘ 1â€“3 mg/kg/d qwk (p)</td><td>Instant;&nbsp;TÂ½â€¯75â€“120â€¯h, 50â€¯%&nbsp;[15â€“40]</td><td>Strong inducer</td><td>Sedation /&nbsp;cognitive decline,&nbsp;bone</td><td>Onceâ€‘daily dosing helps adherence</td><td>Vitâ€¯Dâ€¯+â€¯bone screen</td></tr>\n<tr><td>Phenytoinâ€¯[Dilantin]</td><td>PHT&nbsp;(1938)</td><td>Focal, SE</td><td>Caps, suspÂ§, IV</td><td>$</td><td>Naâº block (zeroâ€‘order)</td><td>300â€¯â†’â€¯600</td><td>5â€¯;â€¯5â€“10&nbsp;(QD)</td><td>â†‘ 100 mg q1â€“2wk (ad); â†‘ 2â€“5 mg/kg/d q1â€“2wk (p)</td><td>5â€¯d;&nbsp;TÂ½â€¯22â€¯h, 90â€¯%&nbsp;[10â€“20]</td><td>Inducer; â†“â€¯OCP, warfarin</td><td>Gingival hyperplasia /&nbsp;DRESS</td><td>Avoid generic switches</td><td>Level qâ€¯6â€“12â€¯m</td></tr>\n<tr><td>Pregabalinâ€¯[Lyrica]</td><td>PGB&nbsp;(2004)</td><td>Adj.*, pain, anxiety</td><td>Caps, soln</td><td>$$</td><td>Î±2Î´â€‘CaÂ²âº mod</td><td>150â€¯â†’â€¯600</td><td>2â€¯;â€¯2â€“10&nbsp;(BID)</td><td>â†‘ 75 mg q1wk (ad); â†‘ 1â€“2 mg/kg/d q1wk (p)</td><td>2â€¯d;&nbsp;TÂ½â€¯6â€¯h, 0â€¯%</td><td>Minimal</td><td>Edema, wt gain /&nbsp;abuse</td><td>Not common in peds</td><td>Weight, mood</td></tr>\n<tr><td>Primidoneâ€¯[Mysoline]</td><td>PRM&nbsp;(1953)</td><td>Focal, tremor</td><td>TabsÂ§</td><td>$</td><td>Proâ€‘drug â†’&nbsp;PB, PEMA</td><td>250â€¯â†’â€¯2000</td><td>5â€¯;â€¯15&nbsp;(TID)</td><td>â†‘ 125 mg q3d (ad); â†‘ 5â€“10 mg/kg/d q3d (p)</td><td>2â€“3â€¯wk;&nbsp;PB&nbsp;TÂ½â€¯120â€¯h</td><td>Inducer (as PB)</td><td>Sedation, depression /&nbsp;osteoporosis</td><td>Rarely used now</td><td>Bone health, levels</td></tr>\n<tr><td>Rufinamideâ€¯[Banzel]</td><td>RUF&nbsp;(2008)</td><td>LGS</td><td>Tabâ€¯Â§; oral&nbsp;susp</td><td>$$</td><td>Prolongs Naâº inactivation</td><td>400â€¯â†’â€¯3200</td><td>10â€¯;â€¯45â€“50&nbsp;(div&nbsp;BID)</td><td>â†‘ 400â€“800 mg q2d (ad); â†‘ 10 mg/kg/d q2d (p)</td><td>2â€“3â€¯d;&nbsp;TÂ½â€¯6â€“10â€¯h, 34â€¯%</td><td>â†“&nbsp;by CBZ/PB; â†‘&nbsp;by&nbsp;VPA</td><td>QTshort, GI upset /&nbsp;DRESS</td><td>Give w/&nbsp;food; screen QT</td><td>ECG baseline if cardiac&nbsp;hx</td></tr>\n<tr><td>Stiripentolâ€¯[Diacomit]</td><td>STP&nbsp;(2018&nbsp;US)</td><td>Dravet adj.</td><td>Capâ€¯/â€¯powderÂ§</td><td>$$$</td><td>GABAâ€¯potentiation (CYP&nbsp;inhib)</td><td>1000â€¯â†’â€¯3000â€¯mg</td><td>15â€¯;â€¯50â€“100 (BIDâ€‘TID)</td><td>â†‘ 250 mg q1â€“2wk (ad); â†‘ 5 mg/kg/d q1â€“2wk (p)</td><td>3â€“5â€¯d;&nbsp;TÂ½â€¯4â€“13â€¯h, 99â€¯%</td><td>â†‘&nbsp;CLB, VPA, PB</td><td>N/V, neutropenia /&nbsp;somnolence</td><td>Must coâ€‘admin with CLB&nbsp;Â±&nbsp;VPA</td><td>CBC, LFT qâ€¯3â€¯m</td></tr>\n<tr><td>Tiagabineâ€¯[Gabitril]</td><td>TGB&nbsp;(1997)</td><td>Adj. focal</td><td>Tabs</td><td>$</td><td>GATâ€‘1 reuptake inhib</td><td>4â€¯â†’â€¯56</td><td>0.1â€¯;â€¯1â€“2&nbsp;(BID)</td><td>â†‘ 4â€“8 mg qwk (ad); â†‘ 0.05 mg/kg/d qwk (p)</td><td>2â€¯d;&nbsp;TÂ½â€¯7â€“9â€¯h, 96â€¯%</td><td>â†“&nbsp;by&nbsp;EIAEDs; â†‘&nbsp;VPA</td><td>Sedation /&nbsp;NCSE in nonâ€‘E</td><td>Avoid offâ€‘label anxiety</td><td>Counsel on dusk dosing</td></tr>\n<tr><td>Topiramateâ€¯[Topamax]</td><td>TPM&nbsp;(1996)</td><td>LGS, IS, migraine</td><td>Tabs, sprinkles, ER</td><td>$â€“$$</td><td>â†‘&nbsp;GABA, Naâº/CaÂ²âº block, AMPA</td><td>25â€¯â†’â€¯400</td><td>1â€¯;â€¯5â€“9&nbsp;(BID)</td><td>â†‘ 25â€“50 mg q1â€“2wk (ad); â†‘ 0.5â€“1 mg/kg/d q1â€“2wk (p)</td><td>4â€¯wk;&nbsp;TÂ½â€¯21â€¯h, 15â€¯%&nbsp;[2â€“25]</td><td>â†“&nbsp;OCP, â†‘&nbsp;by&nbsp;EIAEDs</td><td>Paresthesias, wt loss /&nbsp;nephrolithiasis,&nbsp;anhidrosis</td><td>Encourage fluids; monitor growth</td><td>HCO3 baseline &amp;â€¯periodic</td></tr>\n<tr><td>Valproateâ€¯[Depakote]</td><td>VPA&nbsp;(1978)</td><td>Broad, migraine</td><td>Tabs, sprinkles, IVÂ§</td><td>$â€“$$</td><td>â†‘&nbsp;GABA, Naâº&nbsp;block</td><td>250â€¯â†’â€¯3000</td><td>10â€¯;â€¯20â€“60 (BID)</td><td>â†‘ 5â€“10 mg/kg/d qwk (ad/p)</td><td>2â€“4â€¯d;&nbsp;TÂ½â€¯5â€“15â€¯h, 90â€¯%&nbsp;[50â€“100]</td><td>Enz&nbsp;inhib; â†‘â€¯LTG, PB</td><td>Wt gain, tremor /&nbsp;hepatotox,&nbsp;NTDs</td><td>High teratogenicity</td><td>CBC, LFT (q6m); ammonia </td></tr>\n<tr><td>Vigabatrinâ€¯[Sabril]</td><td>VGB&nbsp;(2009&nbsp;US)</td><td>IS, focal</td><td>PacketsÂ§</td><td>$$</td><td>Irrev&nbsp;GABAâ€‘T inhib</td><td>500â€¯â†’â€¯4000</td><td>25â€¯;â€¯50â€“150&nbsp;(BID)</td><td>â†‘ 500 mg qwk (ad); â†‘ 25â€“50 mg/kg/wk (p)</td><td>2â€¯d;&nbsp;TÂ½â€¯5â€¯h, 0â€¯%</td><td>None</td><td>Weight gain, drowsy /&nbsp;PVFD</td><td>REMS: field&nbsp;perimetry</td><td>Vision (Baseline + q6m)</td></tr>\n<tr><td>Zonisamideâ€¯[Zonegran]</td><td>ZNS&nbsp;(2000)</td><td>Adj. broad</td><td>CapsÂ§</td><td>$$</td><td>Naâº/Tâ€‘CaÂ²âº block, carbonic&nbsp;anhydrase&nbsp;I</td><td>100â€¯â†’â€¯600</td><td>2â€¯;â€¯6â€“12&nbsp;(QDâ€‘BID)</td><td>â†‘ 100 mg q2wk (ad); â†‘ 1â€“2 mg/kg/d q2wk (p)</td><td>2â€“3â€¯wk;&nbsp;TÂ½â€¯60â€¯h, 50â€¯%&nbsp;[10â€“40]</td><td>Sulfa; â†“&nbsp;by&nbsp;EIAEDs</td><td>Anorexia, rash /&nbsp;stones,&nbsp;psychosis</td><td>Warn about sulfa&nbsp;crossâ€‘rxn</td><td>Electrolytes, renal&nbsp;fxn (qâ€¯6â€“12m)</td></tr>\n</tbody>\n</table>\n</div><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/the-height-of-man-rule-schematic-diagram-with-regard-to-dosing-of-children-with.png\" alt=\"Weight-Based Dosing Schematic\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  <figcaption style=\"text-align:center;font-size:0.75rem;color:#64748b;margin-top:0.5rem;font-style:italic;\">Weight-Based Dosing Schematic</figcaption>\n</figure>\n</section>\n<section aria-label=\"Stroke\">\n<div style=\"display:flex;align-items:flex-start;gap:0.875rem;background:#fffbeb;border-left:4px solid #b45309;border-radius:0 10px 10px 0;padding:1rem 1.25rem 1rem 1.25rem;margin:2.5rem 0 1.25rem;\">\n  <span style=\"font-size:1.75rem;line-height:1;flex-shrink:0;margin-top:0.1rem;\" aria-hidden=\"true\">ğŸ§ </span>\n  <div style=\"flex:1;min-width:0;\">\n    <h2 id=\"stroke\" style=\"margin:0 0 0.25rem;padding:0;font-size:1.1rem;font-weight:700;color:#b45309;border:none;background:none;\">Stroke</h2>\n    <p style=\"margin:0;font-size:0.75rem;color:#b45309;opacity:0.85;\">NIHSS scoring guide, pediatric stroke management, and AHA/ASA guidelines</p>\n  </div>\n</div><div class=\"doc-content\" style=\"margin-top:1rem;\"></div><div style=\"margin:1.25rem 0;border-radius:10px;overflow:hidden;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);\">\n  <div style=\"padding:0.6rem 0.875rem;background:#f8fafc;border-bottom:1px solid #e2e8f0;display:flex;align-items:center;justify-content:space-between;gap:0.5rem;flex-wrap:wrap;\">\n    <span style=\"font-size:0.8rem;font-weight:600;color:#1e293b;\">ğŸ“„ AHA/ASA: Management of Stroke in Neonates &amp; Children</span>\n    <a href=\"/pdfs/neuro-on-call/management-of-stroke-in-neonates-and-children-a-scientific-statement-from-the-american-heart.pdf\" target=\"_blank\" rel=\"noopener\" style=\"font-size:0.75rem;color:#2563eb;white-space:nowrap;text-decoration:none;background:#eff6ff;border:1px solid #bfdbfe;border-radius:6px;padding:0.25rem 0.6rem;\">Open / Download â†—</a>\n  </div>\n  <object data=\"/pdfs/neuro-on-call/management-of-stroke-in-neonates-and-children-a-scientific-statement-from-the-american-heart.pdf\" type=\"application/pdf\" width=\"100%\" style=\"display:block;background:#fafafa;\" class=\"pdf-embed\">\n    <div style=\"padding:2rem;text-align:center;\">\n      <p style=\"margin:0 0 0.75rem;color:#64748b;font-size:0.875rem;\">PDF preview not available.</p>\n      <a href=\"/pdfs/neuro-on-call/management-of-stroke-in-neonates-and-children-a-scientific-statement-from-the-american-heart.pdf\" target=\"_blank\" rel=\"noopener\" style=\"color:#2563eb;font-size:0.875rem;\">ğŸ“„ Open PDF</a>\n    </div>\n  </object>\n</div>\n</section>\n\n<section aria-label=\"Pediatric LVO Escalation Pathway\">\n<div style=\"display:flex;align-items:flex-start;gap:0.875rem;background:#fef2f2;border-left:4px solid #dc2626;border-radius:0 10px 10px 0;padding:1rem 1.25rem 1rem 1.25rem;margin:2.5rem 0 1.25rem;\">\n  <span style=\"font-size:1.75rem;line-height:1;flex-shrink:0;margin-top:0.1rem;\" aria-hidden=\"true\">ğŸš¨</span>\n  <div style=\"flex:1;min-width:0;\">\n    <h2 id=\"lvo-escalation\" style=\"margin:0 0 0.25rem;padding:0;font-size:1.1rem;font-weight:700;color:#dc2626;border:none;background:none;\">Pediatric LVO Escalation Pathway</h2>\n    <p style=\"margin:0;font-size:0.75rem;color:#dc2626;opacity:0.85;\">Emergency escalation for suspected pediatric large vessel occlusion requiring endovascular intervention</p>\n  </div>\n</div>\n<div class=\"doc-content\" style=\"margin-top:1rem;\">\n\n<h3>Step 1 â€” Call Anesthesia</h3>\n<ul>\n<li><strong>Age &lt;12 years:</strong> Call <strong>Peds anesthesia</strong> â€” ask if they have availability / can go to NCMC</li>\n<li><strong>Age &gt;12 years:</strong> Call <strong>adult anesthesia at NCMC</strong> â€” ask if they would take the patient</li>\n</ul>\n<ul>\n<li>If <strong>yes</strong> â†’ Call endovascular neurosurgery</li>\n<li>If <strong>no</strong> â†’ Proceed to Step 2</li>\n</ul>\n\n<h3>Step 2 â€” Outside Hospitals Transfer Center â€” Call Multiple</h3>\n<p>Call multiple simultaneously if needed.</p>\n<div class=\"table-wrap\"><table><tbody>\n<tr><th>Hospital</th><th>Transfer Center</th></tr>\n<tr><td>Cincinnati Children's Hospital</td><td><a href=\"tel:+15136369937\"><strong>(513) 636-9937</strong></a></td></tr>\n<tr><td>University of Kentucky Children's Hospital</td><td><a href=\"tel:+18592575522\"><strong>(859) 257-5522</strong></a></td></tr>\n<tr><td>Riley Children's Hospital</td><td><a href=\"tel:+13179633333\"><strong>(317) 963-3333</strong></a></td></tr>\n<tr><td>Vanderbilt Children's Hospital</td><td><a href=\"tel:+16159364444\"><strong>(615) 936-4444</strong></a></td></tr>\n<tr><td>Nationwide Children's Hospital</td><td><a href=\"tel:+16147222000\"><strong>(614) 722-2000</strong></a></td></tr>\n</tbody></table></div>\n\n</div>\n</section>\n<section aria-label=\"Migraine Pathway â€” Quick Reference\">\n<div style=\"display:flex;align-items:flex-start;gap:0.875rem;background:#f0fdfa;border-left:4px solid #0d9488;border-radius:0 10px 10px 0;padding:1rem 1.25rem 1rem 1.25rem;margin:2.5rem 0 1.25rem;\">\n  <span style=\"font-size:1.75rem;line-height:1;flex-shrink:0;margin-top:0.1rem;\" aria-hidden=\"true\">ğŸ¤•</span>\n  <div style=\"flex:1;min-width:0;\">\n    <h2 id=\"migraine-pathway-quick-reference\" style=\"margin:0 0 0.25rem;padding:0;font-size:1.1rem;font-weight:700;color:#0d9488;border:none;background:none;\">Migraine Pathway â€” Quick Reference</h2>\n    <p style=\"margin:0;font-size:0.75rem;color:#0d9488;opacity:0.85;\">Inpatient migraine management pathway diagram (v.1.0 2020)</p>\n  </div>\n</div>\n<div style=\"margin-top:1rem;\">\n  <figure style=\"margin:0;\">\n    <img src=\"/images/neuro-on-call/migraine-pathway.png\" alt=\"Migraine Inpatient Management Pathway 2020\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n    <figcaption style=\"text-align:center;font-size:0.75rem;color:#94a3b8;margin-top:0.5rem;\">Migraine Management Pathway: Inpatient v.1.0 (2020)</figcaption>\n  </figure>\n</div>\n</section>\n<section aria-label=\"Clinical Reference Images\">\n<div style=\"display:flex;align-items:flex-start;gap:0.875rem;background:#f8fafc;border-left:4px solid #475569;border-radius:0 10px 10px 0;padding:1rem 1.25rem 1rem 1.25rem;margin:2.5rem 0 1.25rem;\">\n  <span style=\"font-size:1.75rem;line-height:1;flex-shrink:0;margin-top:0.1rem;\" aria-hidden=\"true\">ğŸ–¼ï¸</span>\n  <div style=\"flex:1;min-width:0;\">\n    <h2 id=\"clinical-reference-images\" style=\"margin:0 0 0.25rem;padding:0;font-size:1.1rem;font-weight:700;color:#475569;border:none;background:none;\">Clinical Reference Images</h2>\n    <p style=\"margin:0;font-size:0.75rem;color:#475569;opacity:0.85;\">Additional visual reference materials for on-call scenarios</p>\n  </div>\n</div><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/img-7641.jpeg\" alt=\"IMG 7641\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  \n</figure><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/img-7642-1-.png\" alt=\"IMG 7642 (1)\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  \n</figure><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/img-7643.jpeg\" alt=\"IMG 7643\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  \n</figure><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/img-7644.jpeg\" alt=\"IMG 7644\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  \n</figure><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/img-7645.jpeg\" alt=\"IMG 7645\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  \n</figure><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/image.png\" alt=\"Image\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  \n</figure><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/image-1-.png\" alt=\"Image (1)\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  \n</figure><figure style=\"margin:1.25rem 0;\">\n  <img src=\"/images/neuro-on-call/image-2-.png\" alt=\"Image (2)\" style=\"max-width:100%;border-radius:10px;border:1px solid #e2e8f0;box-shadow:0 1px 4px rgba(0,0,0,0.08);display:block;margin:0 auto;\">\n  \n</figure>\n</section>\n",
  "imageCount": 11,
  "chunkCount": 5
}